Advanced Gene Editing with CRISPR is a 3 day live remote workshop designed for researchers with entry level experience in CRISPR/Cas9 technology seeking a more in-depth immersion in state-of-art CRISPR [….]
Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug [….]
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.
AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise. Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. REGENXBIO to receive $370 million upfront payment
Investors Eye Gene Therapy Companies and Rapidly Expanding Market – Five Publicly Traded Gene Therapy Companies
This five day live remote workshop is ideal for bench and research scientists who are looking for a solid foundation in RNA-Seq, from application, experimental design and sample preparation to [….]
This rigorous three day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. hands-on introduction to gene editing iPSCs using CRISPR/Cas9. [….]
American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.
Discovery Labs suburban Philadelphia campus gained a new tenant, the University of Pennsylvania Gene Therapy Program (GTP), which focuses on the development of AAV-based gene therapies for rare and orphan genetic diseases with high unmet needs.
This remote rigorous three-day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. laboratory introduction to CRISPR toolkit. Taught by active [….]